Jun 2, 2009
Additional funding through shares emission and warrant scheme

North Murray AS has exercised warrant.

Further to Company communication of 24th March 2009; North Murray AS has exercised all warrants to purchase 23.622 shares at NOK 600 in Lytix Biopharma. Chairman of the board, Knut Eidissen, express his satisfaction of Mr. Munthe becoming a part owner of Lytix Biopharma.

For further information contact:

Chairman of the Board, Knut Eidissen (+47 916 17 707)

CEO Gunnar Sælid (+47 911 92 330)